Parma (Italy), September 6th, 2021 – Chiesi, an international research-focused healthcare group (Chiesi Group), organizes the Symposium Unlock every breath: finding the right key to improve respiratory therapy during the 2021 ERS International Congress. The ERS Congress is the hallmark event dedicated to respiratory health for the scientific and medical community, with the aim of sharing the latest findings on pathologies and treatments. The Symposium will be held on September 7th from 13:00 to 14:00 CET and it will be available online on Channel 6 of the Congress, taking place in fully virtual mode.
Dave Singh, Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, member of the European Respiratory Society and of the British Pharmacology Society is chairing the event. Three speakers, internationally recognised for their specialization in these diseases will present the latest findings in the treatment of asthma and COPD.
Monica Kraft, physician, researcher and Chair of the Department of Medicine at the University of Arizona College of Medicine-Tucson will speak about the crucial role small airways and extrafine formulations play in the treatment of asthma and COPD.
Omar Usmani, Reader in Respiratory Medicine and Consultant Physician at the National Heart and Lung Institute (NHLI), Imperial College London, Royal Brompton Hospital (RBH) & St Mary Hospital London, is an internationally recognized expert on aerosol science and inhalation medicine. He will delve deeper into the potential of inhalation devices and the risks of their incorrect use or the lack of therapeutic adherence by patients.
Alberto Papi, Professor of Respiratory Medicine at the Department of Medicine at the University of Ferrara and Head of the Respiratory Unit of the Emergency Department at the Policlinico Universitario Sant’Anna of Ferrara, will present new recommendations from the Global Initiative for Asthma (GINA) and highlight the new triple therapy approach which is now recommended for some patients also in this indication.
"With this prestigious Symposium, Chiesi Group confirms its commitment dating over 40 years to promoting people’s health in the respiratory field, to which the Chiesi Air area is dedicated. We intend to support the success of this international congress, which has been totally renewed and digitalised due to the persistent pandemic, promoting new ways for updating and knowledge sharing among the leading experts, crucial for clinical and scientific progress" explains Gabriele Nicolini, Head of Global Medical Affairs, Chiesi Group.
As part of this same commitment, in 2021 the Chiesi Group has offered its unconditional support for the realisation of the Breathe in the Digital Evolution communications campaign which has been developed and promoted by AIM Group International and dedicated to public opinion and health professionals. The aim of the campaign is to raise awareness about lung health, air quality and sustainable practices. The www.breatheinthedigitalevolution.com platform offers content, videos, infographics and insights to both health professionals and the public. It also offers suggestions on how to promote environmental sustainability and air quality for optimum breathing. These topics are particularly important for the Chiesi Group, a Benefit Corporation and since 2019 the largest pharmaceutical group in the world awarded B Corp certification, who has committed to become carbon neutral by the end of 2035.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.
For further information: www.chiesi.com
Press Office Manager
Phone +39 339 5897483,